

In re Application of: Toshio ARIYASU, et al.  
 Serial No.: 09/063,778  
 Filed: April 22, 1998  
 For: HEDGEHOG PROTEIN



Art Unit: 1646  
 Examiner: C. KAUFMAN  
 Washington, D.C.  
 Atty.'s Docket: ARIYASU=1  
 Date: January 10, 2001

RECEIVED  
 16 2001  
 ENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
 Washington, D.C. 20231  
 Sir:

Transmitted herewith is an [XX] Amendment [ ]  
 in the above-identified application.

- [ ] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.  
 [ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.  
 [XX] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)			(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Additional Fee		Rate	Additional Fee
Total	5	Minus	22	0		x 9	\$		x18	\$
Indep.	2	Minus	3	0		x40	\$		x80	\$
First Presentation of Multiple Dependent Claim						135	\$		+270	\$
TOTAL ADDITIONAL CLAIMS FEE							\$		Total	\$

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.  
 \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
 \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.  
 The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time  
 If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity		Other Than Small Entity	
Response Filed Within		Response Filed Within	
[ ] First	- \$ 55.00	[ ] First	- \$ 110.00
[ ] Second	- \$195.00	[ ] Second	- \$ 390.00
[ ] Third	- \$445.00	[ ] Third	- \$ 890.00
[ ] Fourth	- \$695.00	[ ] Fourth	- \$1390.00

[ ] Less fees (\$ ) already paid for months extension of time on

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ . A duplicate copy of this sheet is attached.

[ ] A check in the amount of \$ is attached (check no. ).

[ ] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK  
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528  
 Telephone: (202) 628-5197

By:   
 John W. Kornbau  
 Registration No. 25,884

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: ARIYASU=

In re Application of:

Toshio ARIYASU, et al.

Serial No.: 09/063,778

Filed: April 22, 1998

For: HEDGEHOG PROTEIN

Art Unit: 1646

Examiner: C. KAUFMAN

Washington D.C.

January 10, 2001



RECEIVED  
1/9/2001

AMENDMENT

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

In response to the Office Action of October 10, 2000,  
please enter the following amendment:

IN THE CLAIMS

Please replace original claim 24 with new claim 24 as  
follows:

24. A purified human Desert hedgehog protein  
obtainable by expression of a DNA which comprises a 528-  
nucleotide sequence amplifiable ~~by~~ from a human cDNA  
polymerase chain reaction using a sense primer having the  
nucleotide sequence of SEQ ID NO:27 in combination with an  
antisense primer having the nucleotide sequence of SEQ ID  
NO:28 and <sup>which</sup> encodes a contiguous amino acid sequence which  
contains the amino acid residue Glu-155.